Geron Corporation

Geron Corporation company information, Employees & Contact Information

Geron is a biopharmaceutical company that is charting a new course with the goal to deliver innovative treatment options for people living with blood cancer. Our tireless pursuit to improve outcomes for these patients resulted in the U.S. approval of the first ever telomerase inhibitor for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As the sole company with an oligonucleotide telomerase inhibitor approved by the FDA, we feel a deep urgency to bring the potential power of telomerase inhibition to patients in need. We are conducting research in other blood cancers with high unmet need beyond LR-MDS, with ongoing clinical trials across other hematologic malignancies, including a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF). We are proud of the impact this Nobel-winning science is having in the fight against blood cancers. At Geron, we are united by a shared purpose: Every individual in every role can meaningfully contribute to our mission to change lives by changing the course of blood cancer. With a culture rooted in courage and determination, we will continue to innovate and pursue new possibilities for patients. To learn more, visit www.geron.com. Geron’s Community Guidelines: https://www.geron.com/CommunityGuidelines/

Company Details

Employees
399
Founded
-
Address
Foster City, California
Phone
6504737718
Email
in****@****ron.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
geron.com
HQ
Foster City, California
Looking for a particular Geron Corporation employee's phone or email?

Geron Corporation Questions

News

Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025 - Yahoo Finance

Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025 Yahoo Finance

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Geron Corporation Announces Executive Leadership Transitions and Appointments - GlobeNewswire

Geron Corporation Announces Executive Leadership Transitions and Appointments GlobeNewswire

Nearly 1M Shares: Geron Corporation's Major Equity Grant Package Draws 16 New Biotech Talents - Stock Titan

Nearly 1M Shares: Geron Corporation's Major Equity Grant Package Draws 16 New Biotech Talents Stock Titan

Geron to Participate in the 2025 Wells Fargo Healthcare Conference - Business Wire

Geron to Participate in the 2025 Wells Fargo Healthcare Conference Business Wire

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Yahoo Finance

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights Yahoo Finance

Geron Appoints Harout Semerjian as President and Chief Executive Officer - Business Wire

Geron Appoints Harout Semerjian as President and Chief Executive Officer Business Wire

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights - Business Wire

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights Business Wire

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program - Business Wire

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program Business Wire

Geron Corporation Announces Departure of Chief Executive Officer - Business Wire

Geron Corporation Announces Departure of Chief Executive Officer Business Wire

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS - Business Wire

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS Business Wire

Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies - Yahoo Finance

Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies Yahoo Finance

Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors - Business Wire

Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors Business Wire

FDA Approves Geron Corporation’s Rytelo to Treat Adults with Lower-Risk Myelodysplastic Syndromes - Pharmaceutical Executive

FDA Approves Geron Corporation’s Rytelo to Treat Adults with Lower-Risk Myelodysplastic Syndromes Pharmaceutical Executive

Geron to Announce Third Quarter 2023 Financial Results on November 2, - Business Wire

Geron to Announce Third Quarter 2023 Financial Results on November 2, Business Wire

Geron to Announce First Quarter 2023 Financial Results on May 11, 2023 - Business Wire

Geron to Announce First Quarter 2023 Financial Results on May 11, 2023 Business Wire

Geron to Announce Fourth Quarter and Full-Year 2022 Financial Results on March 16, 2023 - Business Wire

Geron to Announce Fourth Quarter and Full-Year 2022 Financial Results on March 16, 2023 Business Wire

Geron Announces Conference Call for Top-Line Results from IMerge Phase 3 - Business Wire

Geron Announces Conference Call for Top-Line Results from IMerge Phase 3 Business Wire

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results - Stock Titan

Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results Stock Titan

Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S. - Business Wire

Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S. Business Wire

Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting - Stock Titan

Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting Stock Titan

Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors - FinancialContent

Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors FinancialContent

Top Geron Corporation Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant